CRT Inc.

CRT Inc. provides oncology-focused technology transfer and development expertise to leading US not-for-profit research institutions and represents CRT Ltd. in licensing discussions with US biopharmaceutical companies. CRT Inc. is based in Cambridge, Massachusetts.

Through partnership with CRT Inc., US academics are able to bridge the fundamental development gap between exploratory research and industrial development of diagnostics and therapeutics in oncology. Collaborators access over 20 years experience of oncology-focused commercialisation of academic-based discoveries and biotherapeutic and drug discovery expertise within CRT’s Development Laboratories.

Dr Larry Steranka, CRT Inc.’s Managing Director, was previously the Executive Director of Brandeis University’s Office of Technology Licensing, and immediately before that, an Associate Director for Licensing at Harvard University’s Office of Technology and Trademark Licensing. Dr Steranka has also held senior positions within major pharmaceutical and biotechnology companies.

CRT Inc., a US subsidiary of Cancer Research Technology Ltd., was established in 2006.